BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BLEX 404 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BLEX 404\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03301805-2403@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BLEX 404: Phase 2 readout est. (NCT03301805)
DESCRIPTION:BLEX 404\, phase 2.\nStudy: A Phase II\, EvaluateBLEX 404 Combi
 ned With Gemcitabine Monotherapy With Pancreatic Cancer\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/blex-404#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03301805
URL:https://assetmemo.bio/drug/blex-404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05764928-2403@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BLEX 404: Phase 1/2 readout est. (NCT05764928)
DESCRIPTION:BLEX 404\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Eval
 uate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetre
 xed + Cisplatin Therapy\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/blex-404#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05764928
URL:https://assetmemo.bio/drug/blex-404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02802423-2403@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:BLEX 404: Phase 1/2 readout est. (NCT02802423)
DESCRIPTION:BLEX 404\, phase 1/2.\nStudy: Phase I/II\, Evaluate the Safety 
 and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastat
 ic Triple Negative Breast Cancer.\nEstimated primary completion: 30 April 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/blex-404#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02802423
URL:https://assetmemo.bio/drug/blex-404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02944955-2403@assetmemo.bio
DTSTAMP:20261121T005400Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BLEX 404: Phase 2 readout est. (NCT02944955)
DESCRIPTION:BLEX 404\, phase 2.\nStudy: A Study of BLEX 404 Oral Liquid in 
 Patients With International Prognostic Scoring System (IPSS) Intermediate-
 1\, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic
  Myelomonocytic Leukemia (CMML)\nEstimated primary completion: 31 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/blex-404#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02944955
URL:https://assetmemo.bio/drug/blex-404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
